These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35986757)

  • 1. FLOT and CROSS chemotherapy regimens alter the frequency of CD27
    Davern M; Donlon NE; Sheppard AS; Majcher KD; Connell FO; Heeran AB; Grant M; Farrell RA; Hayes C; Bracken-Clarke D; Conroy MJ; Foley E; Toole DO; Bhardwaj A; Ravi N; Reynolds JV; Maher SG; Sullivan JO; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3753-3774. PubMed ID: 35986757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.
    Davern M; Donlon NE; O' Connell F; Sheppard AD; Hayes C; King R; Temperley H; Butler C; Bhardwaj A; Moore J; Bracken-Clarke D; Donohoe C; Ravi N; Reynolds JV; Maher SG; Conroy MJ; Lysaght J
    Transl Oncol; 2022 Jun; 20():101406. PubMed ID: 35366537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.
    Davern M; Bracken-Clarke D; Donlon NE; Sheppard AD; Connell FO; Heeran AB; Majcher K; Conroy MJ; Mylod E; Butler C; Donohoe C; Donnell DO; Lowery M; Bhardwaj A; Ravi N; Melo AA; Sullivan JO; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6583-6599. PubMed ID: 36790524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
    Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
    Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.
    Davern M; Donlon NE; Sheppard A; Connell FO; Hayes C; Bhardwaj A; Foley E; Toole DO; Lynam-Lennon N; Ravi N; Reynolds JV; Maher SG; Lysaght J
    Transl Oncol; 2021 Jun; 14(6):101062. PubMed ID: 33765543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.
    Davern M; Gaughan C; O' Connell F; Moran B; Mylod E; Sheppard AD; Ramjit S; Yun-Tong Kung J; Phelan JJ; Davey MG; Ryan EJ; Butler C; Quinn L; Howard C; Tone E; Phoenix E; Butt WT; Lynam-Lennon N; Maher SG; Ravi N; Donohoe CL; Reynolds JV; Lysaght J; Donlon NE
    Front Immunol; 2023; 14():1150754. PubMed ID: 37359545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
    Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
    Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis.
    Chidambaram S; Sounderajah V; Maynard N; Owen R; Markar SR
    Dis Esophagus; 2023 Jan; 36(2):. PubMed ID: 36151055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site distribution of oesophagogastric cancer.
    Byrne JP; Mathers JM; Parry JM; Attwood SE; Bancewicz J; Woodman CB
    J Clin Pathol; 2002 Mar; 55(3):191-4. PubMed ID: 11896070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genomic landscape of oesophagogastric junctional adenocarcinoma.
    Chong IY; Cunningham D; Barber LJ; Campbell J; Chen L; Kozarewa I; Fenwick K; Assiotis I; Guettler S; Garcia-Murillas I; Awan S; Lambros M; Starling N; Wotherspoon A; Stamp G; Gonzalez-de-Castro D; Benson M; Chau I; Hulkki S; Nohadani M; Eltahir Z; Lemnrau A; Orr N; Rao S; Lord CJ; Ashworth A
    J Pathol; 2013 Nov; 231(3):301-10. PubMed ID: 24308032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
    Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
    Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers.
    Shahnam A; Nindra U; McNamee N; Yoon R; Asghari R; Ng W; Karikios D; Wong M
    Gastrointest Tumors; 2023; 10(1):19-28. PubMed ID: 37901653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
    Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.
    Gutting T; Schulte N; Belle S; Betge J; Härtel N; Wilke J; Weers J; Ebert MP; Zhan T
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):503-507. PubMed ID: 31826054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.